Polatuzumab vedotin plus bendamustine and rituximab in relapsed / refractory diffuse large B-cell lymphoma: updated results of a randomized phase Ib / II study and preliminary results of a single arm extension

Idecabtagen Vicleucel (Ide-Cel, bb2121), an anti-BCMA-directed CAR-T-cell therapy for the treatment of patients with relapsed and refractory multiple myeloma: Update of the KarMMa study

Pevonedistat (P) plus Azacitidine (A) vs A Monotherapy in High Risk Myelodysplastic Syndromes (HR-MDS): Results of Efficacy and Safety in Study P-2001 (NCT02610777)

The oral version of azacitidine extends overall and relapse-free survival in patients with acute myeloid leukemia (AML) in the 1st remission after intensive chemotherapy (IC) with or without consolidation: results of the QUAZAR AML-001 maintenance therapy study

Activity of decitabine (DAC) in combination with all-trans-retinoic acid (ATRA) in oligoblastic AML: results of a randomized 2x2 phase II study (DECIDER)

Health-related quality of life (Hrqol) with oral azacitidine formulation in patients with acute myeloid leukemia (AML) in 1st remission after intensive chemotherapy (IC): results of the phase 3 QUAZAR AML-001 maintenance therapy study

Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapsed / refractory T-cell lymphomas: preliminary results of the experimental arm of the level study

ECHELON-2, (NCT01777152), 5-year results of a randomized, double-blind phase 3 study of brentuximab-vedotin + CHP on the front line against CHOP in patients with CD30-positive peripheral T-cell lymphoma

Glofitamab step-up dosing: updated efficacy data show high rates of complete response in multiple pretreated patients with relapsed / refractory (R / R) non-Hodgkin lymphoma (NHL)

Results of the ZUMA-3 phase 2 study of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R / R B-ALL )

Updated results of tucatinib versus placebo in combination with trastuzumab and capecitabine (HER2CLIMB study) in patients with previously treated HER2-positive metastatic breast cancer with and without brain metastases

Evaluation of sacituzumab govitecan (SG) in patients (pts) with metastatic triple negative breast cancer (mTNBC) in the phase 3 ASCENT study, after previous neoadjuvant / adjuvant chemotherapy

Chimeric antigen receptor (CAR) T cells of the third generation for the treatment of patients with diseases of the lymphatic system - results of the Heidelberg CAR-1 (HD-CAR-1) study

Bosutinib (BOS) in the second line of chronic myeloid leukemia (CML) in the CP: final 10-year data of the phase 1/2 study

PD-1 expression and molecular relapse risk in patients with chronic myeloid leukemia and nilotinib stop attempt